European Archives - Page 107 of 1473 - European Medical Journal

Immunohistochemical Biomarkers for Prognostic Stratification in Metastatic Prostate Cancer

New evidence shows PSA and Ki-67 tumour expression may help predict progression and guide treatment decisions in metastatic castration-sensitive prostate cancer.

Rollout of AI Scribe Tools Transform NHS Consultations

AI-scribe tools cut admin time, boost patient interaction, and could reshape how NHS clinicians deliver care nationwide.

AI Models Combine Genomics and Demographics to Predict Gastric Cancer Risk

New research shows supervised machine learning models combining Helicobacter pylori genomic data with patient demographics can accurately predict gastric cancer risk.

Data Support Outpatient Stem Cell Mobilisation Safety

A real-world analysis suggests outpatient stem-cell mobilisation in multiple myeloma could safely reduce hospital admissions and bed use through risk stratification and machine learning prediction.

Vitamin K Antagonists Linked to Lower Short-Term Risk in COPD

Nationwide cohort data suggest vitamin K antagonists are linked to a lower 1-year risk of severe COPD exacerbation or death compared with DOACs.

Light-Triggered Microneedle Patch Aimed at IVF Injections

Light-triggered microneedle patch was tested to deliver IVF hormones on demand using near-infrared light, potentially reducing daily injection burden.

Emerging Prostate Cancer Diagnostics: Hashim Ahmed

Emerging Prostate Cancer Diagnostics: Hashim Ahmed. Chair and Professor of Urology, Imperial College London, UK..

5 Feb 2026

The first and only approved dual inhibitor of IL-17A and IL-17F1-6

BIMZELX® Demonstrated Deep and Sustained Efficacy to 3 Years Across Multiple Disease Domains of PsA and the Full axSpA Spectrum…

Onc Now: A Career at the Cutting Edge of Nuclear Medicine

Nuclear medicine has undergone extraordinary transformation over the past decades, and it continues to redefine how cancer is diagnosed and…

AI tool

AI Tool Guides Care for Cancer Heart Attacks

The newly developed AI tool, known as ONCO-ACS, was designed specifically to predict six-month mortality, major bleeding, and ischaemic events in patients with cancer and acute coronary syndrome.